Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Strong diagnostic performance of plasma ptau217 for CSF biomarker-defined young-onset Alzheimer disease in a diagnostically heterogeneous clinical cohort

Eratne, Dhamidhu ; Li, Qiao Xin ; Lewis, Courtney ; Dang, Christa ; Kang, Matthew J.Y. ; Grewal, Jasleen ; Loi, Samantha ; Walterfang, Mark ; Evans, Andrew H. and Malpas, Charles B. , et al. (2025) In Journal of Neurology 272(1).
Abstract

Objective: We investigated diagnostic utility of phosphorylated tau 217 and 181 (ptau217, ptau181), glial fibrillary acidic protein (GFAP), amyloid beta 42 and 40 (Aβ42, Aβ40), and neurofilament light (NfL) to distinguish biomarker-defined Alzheimer disease (AD) from non-AD conditions, in a heterogenous clinical cohort of younger people. Methods: Plasma biomarkers were analysed using ultrasensitive technology, and compared in patients with CSF Alzheimer disease profiles (A+T+) to other CSF profiles (Other). Results: Seventy-nine patients were included, median age 60.8 years: 16 A+T+, 63 Other. Ptau217, ptau181, GFAP were significantly elevated in A+T+ compared to Other (3.67 vs 1.12 pg/mL, 3.87 vs 1.79 pg/mL, 189 vs 80 pg/mL,... (More)

Objective: We investigated diagnostic utility of phosphorylated tau 217 and 181 (ptau217, ptau181), glial fibrillary acidic protein (GFAP), amyloid beta 42 and 40 (Aβ42, Aβ40), and neurofilament light (NfL) to distinguish biomarker-defined Alzheimer disease (AD) from non-AD conditions, in a heterogenous clinical cohort of younger people. Methods: Plasma biomarkers were analysed using ultrasensitive technology, and compared in patients with CSF Alzheimer disease profiles (A+T+) to other CSF profiles (Other). Results: Seventy-nine patients were included, median age 60.8 years: 16 A+T+, 63 Other. Ptau217, ptau181, GFAP were significantly elevated in A+T+ compared to Other (3.67 vs 1.12 pg/mL, 3.87 vs 1.79 pg/mL, 189 vs 80 pg/mL, respectively). ptau217 distinguished AD from Other with 90% accuracy (88% specificity, 100% sensitivity). ptau217 also demonstrated strong diagnostic performance for clinically diagnosed AD. Conclusions: Plasma ptau217 has strong diagnostic performance in distinguishing CSF biomarker-defined AD in a clinically relevant, younger cohort of people with symptoms, adding further weight for a simple diagnostic blood test for AD as a cause of a patient’s symptoms.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
contributor
LU and LU orcid
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer’s disease, Biomarker, Dementia, Diagnosis, ptau217
in
Journal of Neurology
volume
272
issue
1
article number
25
publisher
Springer
external identifiers
  • scopus:85212205227
  • pmid:39666133
ISSN
0340-5354
DOI
10.1007/s00415-024-12732-3
language
English
LU publication?
yes
additional info
Publisher Copyright: © Springer-Verlag GmbH Germany, part of Springer Nature 2024.
id
39941488-a6b2-4e8d-9779-d9d30a2ef92c
date added to LUP
2025-01-05 08:52:27
date last changed
2025-06-11 10:50:46
@article{39941488-a6b2-4e8d-9779-d9d30a2ef92c,
  abstract     = {{<p>Objective: We investigated diagnostic utility of phosphorylated tau 217 and 181 (ptau217, ptau181), glial fibrillary acidic protein (GFAP), amyloid beta 42 and 40 (Aβ42, Aβ40), and neurofilament light (NfL) to distinguish biomarker-defined Alzheimer disease (AD) from non-AD conditions, in a heterogenous clinical cohort of younger people. Methods: Plasma biomarkers were analysed using ultrasensitive technology, and compared in patients with CSF Alzheimer disease profiles (A+T+) to other CSF profiles (Other). Results: Seventy-nine patients were included, median age 60.8 years: 16 A+T+, 63 Other. Ptau217, ptau181, GFAP were significantly elevated in A+T+ compared to Other (3.67 vs 1.12 pg/mL, 3.87 vs 1.79 pg/mL, 189 vs 80 pg/mL, respectively). ptau217 distinguished AD from Other with 90% accuracy (88% specificity, 100% sensitivity). ptau217 also demonstrated strong diagnostic performance for clinically diagnosed AD. Conclusions: Plasma ptau217 has strong diagnostic performance in distinguishing CSF biomarker-defined AD in a clinically relevant, younger cohort of people with symptoms, adding further weight for a simple diagnostic blood test for AD as a cause of a patient’s symptoms.</p>}},
  author       = {{Eratne, Dhamidhu and Li, Qiao Xin and Lewis, Courtney and Dang, Christa and Kang, Matthew J.Y. and Grewal, Jasleen and Loi, Samantha and Walterfang, Mark and Evans, Andrew H. and Malpas, Charles B. and Pedrini, Steve and Martins, Ralph and Chatterjee, Pratishtha and Zetterberg, Henrik and Blennow, Kaj and Berkovic, Samuel F. and Santillo, Alexander F. and Collins, Steven and Masters, Colin L. and Velakoulis, Dennis}},
  issn         = {{0340-5354}},
  keywords     = {{Alzheimer’s disease; Biomarker; Dementia; Diagnosis; ptau217}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{Springer}},
  series       = {{Journal of Neurology}},
  title        = {{Strong diagnostic performance of plasma ptau217 for CSF biomarker-defined young-onset Alzheimer disease in a diagnostically heterogeneous clinical cohort}},
  url          = {{http://dx.doi.org/10.1007/s00415-024-12732-3}},
  doi          = {{10.1007/s00415-024-12732-3}},
  volume       = {{272}},
  year         = {{2025}},
}